Dr Reddy's Laboratories, an integrated global pharmaceutical company, has launched Memantine Hydrochloride Tablets, a therapeutic equivalent generic version of NAMENDA (memantine HCI) tablets in the US market on Jul. 12, 2015. This ANDA was approved by the United States Food & Drug Administration.

According to IMS Health, the NAMENDA tablets brand had U.S. sales of approximately USD 1.4 billion MAT for the most recent twelve months ending in May 2015.

Dr Reddy's Laboratories, Memantine Hydrochloride tablets-5 mg is available in bottle count size of 60 and the Memantine Hydrochloride tablets-10 mg is available in bottle count sizes of 60 and 500.

Shares of the company gained Rs 16.6, or 0.44%, to settle at Rs 3,758.75. The total volume of shares traded was 18,412 at the BSE (Monday).